Smith & Nephew SNATS, Inc. (NYSE:SNN) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Consensus "Hold": Five brokerages covering Smith & Nephew SNATS rate the stock a consensus Hold (four holds, one strong-buy) with an average 12‑month price target of $36.25.
• Recent results and trading: the company reported quarterly earnings of $29.55 per share on $1.60 billion in revenue, and shares opened at $31.62 with a 52‑week range of $23.91–$38.79 and 50/200‑day moving averages near $34.3.
• Dividend announced: A $0.482 dividend was declared payable May 27 (ex‑dividend March 27), noted in the article with a reported yield of 304.0%.

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $36.25.

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Wall Street Zen raised shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a report on Sunday. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an "outperform" rating to a "sector perform" rating in a research report on Monday, December 15th. Finally, Canaccord Genuity Group lifted their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a "hold" rating in a report on Thursday, March 5th.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several institutional investors have recently made changes to their positions in SNN. Garner Asset Management Corp bought a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth approximately $27,000. Arax Advisory Partners grew its stake in Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider's stock worth $32,000 after buying an additional 569 shares during the last quarter. Advisors Asset Management Inc. bought a new position in Smith & Nephew SNATS during the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Smith & Nephew SNATS in the third quarter worth $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at $43,000. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Trading Down 0.1%

NYSE:SNN opened at $31.62 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The business's 50 day moving average is $34.27 and its two-hundred day moving average is $34.34. Smith & Nephew SNATS has a 52 week low of $23.91 and a 52 week high of $38.79.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The firm had revenue of $1.60 billion during the quarter. On average, research analysts predict that Smith & Nephew SNATS will post 1.69 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be issued a $0.482 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a yield of 304.0%.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.